Natus Medical Inc (BABY) Expected to Post Quarterly Sales of $136.64 Million

Analysts forecast that Natus Medical Inc (NASDAQ:BABY) will report $136.64 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Natus Medical’s earnings. The highest sales estimate is $137.32 million and the lowest is $136.00 million. Natus Medical reported sales of $131.44 million during the same quarter last year, which indicates a positive year over year growth rate of 4%. The business is scheduled to issue its next quarterly earnings results before the market opens on Wednesday, February 13th.

On average, analysts expect that Natus Medical will report full year sales of $526.54 million for the current year, with estimates ranging from $525.90 million to $527.22 million. For the next year, analysts expect that the business will post sales of $541.60 million, with estimates ranging from $535.00 million to $553.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Natus Medical.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.42 by ($0.02). The company had revenue of $130.60 million during the quarter, compared to analysts’ expectations of $132.92 million. Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.40 EPS.

Several analysts have recently commented on BABY shares. ValuEngine upgraded shares of Natus Medical from a “hold” rating to a “buy” rating in a research note on Thursday. BidaskClub upgraded shares of Natus Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, December 25th. Finally, Roth Capital set a $36.00 target price on shares of Natus Medical and gave the company a “buy” rating in a report on Thursday, October 25th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $42.50.

NASDAQ:BABY traded down $0.06 during trading hours on Friday, reaching $34.32. 202,697 shares of the company’s stock were exchanged, compared to its average volume of 310,925. The stock has a market cap of $1.15 billion, a P/E ratio of 23.67 and a beta of 0.53. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.62 and a quick ratio of 1.89. Natus Medical has a 1-year low of $27.69 and a 1-year high of $37.95.

In related news, Director Ken Ludlum sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $31.02, for a total value of $930,600.00. Following the completion of the sale, the director now directly owns 73,957 shares in the company, valued at $2,294,146.14. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Robert A. Gunst sold 14,750 shares of the business’s stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $33.54, for a total transaction of $494,715.00. Following the completion of the sale, the director now owns 32,392 shares of the company’s stock, valued at $1,086,427.68. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its position in Natus Medical by 7.7% during the second quarter. Wells Fargo & Company MN now owns 212,752 shares of the medical equipment provider’s stock valued at $7,341,000 after buying an additional 15,208 shares in the last quarter. Fenimore Asset Management Inc. increased its stake in shares of Natus Medical by 20.2% in the third quarter. Fenimore Asset Management Inc. now owns 392,145 shares of the medical equipment provider’s stock worth $13,980,000 after buying an additional 65,795 shares during the last quarter. Rutabaga Capital Management LLC MA bought a new stake in shares of Natus Medical in the third quarter worth $9,272,000. Rhumbline Advisers increased its stake in shares of Natus Medical by 4.1% in the second quarter. Rhumbline Advisers now owns 81,441 shares of the medical equipment provider’s stock worth $2,810,000 after buying an additional 3,172 shares during the last quarter. Finally, Polaris Capital Management LLC increased its stake in shares of Natus Medical by 19.9% in the third quarter. Polaris Capital Management LLC now owns 79,420 shares of the medical equipment provider’s stock worth $2,831,000 after buying an additional 13,200 shares during the last quarter. 94.45% of the stock is currently owned by hedge funds and other institutional investors.

Natus Medical Company Profile

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Further Reading: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply